Skip to main content

Research Repository

Advanced Search

Ustekinumab for the treatment of Crohn's disease: can it find its niche?

Ebby G., Simon; Subrata, Ghosh; Marietta, Iacucci; Moran, Gordon


Simon Ebby G.

Ghosh Subrata

Iacucci Marietta

Professor of Gastroenterology


Crohn’s disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn’s disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option. It is approved for use in psoriasis and psoriatic arthritis, and has now been evaluated in phase II trials for moderate-to-severe Crohn’s disease. We here review the published literature and describe a potential clinical role for its use in this disease cohort.


Ebby G., S., Subrata, G., Marietta, I., & Moran, G. (2016). Ustekinumab for the treatment of Crohn's disease: can it find its niche?. Therapeutic Advances in Gastroenterology, 9(1), 26-36.

Journal Article Type Article
Acceptance Date Oct 1, 2015
Online Publication Date Nov 26, 2015
Publication Date Jan 1, 2016
Deposit Date Dec 13, 2018
Journal Therapeutic Advances in Gastroenterology
Print ISSN 1756-283X
Electronic ISSN 1756-2848
Publisher SAGE Publications
Peer Reviewed Peer Reviewed
Volume 9
Issue 1
Pages 26-36
Public URL
Publisher URL
Additional Information Date of acceptance is estimated.